Quick Answer
KIORA PHARMACEUTICALS INC reported Diluted EPS of $2.64 per share (loss) for fiscal year 2025.
KIORA PHARMACEUTICALS INC Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.64 | -403.4% |
| 2024 | $0.87 | +103.6% |
| 2023 | -$24.25 | -30.7% |
| 2022 | -$18.55 | +67.5% |
| 2021 | -$57.12 | -3127.1% |
| 2020 | -$1.77 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.01 | +101.2% | +101.9% |
| June 30, 2025 | -$0.54 | -1.9% | -3.8% |
| March 31, 2025 | -$0.52 | -115.0% | +35.8% |
| September 30, 2024 | -$0.81 | +88.9% | -52.8% |
| June 30, 2024 | -$0.53 | +92.6% | -115.3% |
| March 31, 2024 | $3.46 | +446.0% | +147.4% |
| September 30, 2023 | -$7.30 | -21.1% | -2.1% |
| June 30, 2023 | -$7.15 | -3872.2% | -615.0% |
- KIORA PHARMACEUTICALS INC showed a decrease of -403.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, KIORA PHARMACEUTICALS INC’s diluted eps has declined by 49.2% (from $1.77 per share (loss) to $2.64 per share (loss)).
- The most recent figure is from KIORA PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: